Sarepta Therapeutics (SRPT) to Release Quarterly Earnings on Monday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to be issuing its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of $0.02 per share and revenue of $331.51 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. The company had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm’s quarterly revenue was up 68.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.07 earnings per share. On average, analysts expect Sarepta Therapeutics to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $24.01 on Friday. The firm has a market cap of $2.35 billion, a P/E ratio of -27.60 and a beta of 0.51. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $138.81. The business’s 50 day moving average is $20.23 and its 200-day moving average is $26.94.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on SRPT shares. Oppenheimer upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $30.00 to $37.00 in a research note on Tuesday, July 29th. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. Guggenheim reissued a “buy” rating and set a $22.00 price target on shares of Sarepta Therapeutics in a research report on Monday, September 15th. Baird R W downgraded Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Finally, JPMorgan Chase & Co. raised Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price target on the stock in a research report on Tuesday, July 29th. Eight analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and seven have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $34.50.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the business. FORA Capital LLC boosted its holdings in shares of Sarepta Therapeutics by 1,442.4% in the 2nd quarter. FORA Capital LLC now owns 93,189 shares of the biotechnology company’s stock valued at $1,594,000 after purchasing an additional 87,147 shares in the last quarter. California Public Employees Retirement System boosted its holdings in shares of Sarepta Therapeutics by 7.1% in the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock valued at $1,972,000 after purchasing an additional 7,665 shares in the last quarter. PDT Partners LLC boosted its holdings in shares of Sarepta Therapeutics by 116.1% in the 2nd quarter. PDT Partners LLC now owns 116,246 shares of the biotechnology company’s stock valued at $1,988,000 after purchasing an additional 62,465 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Sarepta Therapeutics by 59.2% in the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock valued at $10,731,000 after purchasing an additional 233,391 shares in the last quarter. Finally, MPM Bioimpact LLC acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $5,501,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.